Argenx Stock Struggles 0.21 as Daily Volume Ranks 489th Amid High-Profile Partnership with Monica Seles to Boost MG Awareness

On August 12, 2025, argenx (ARGX) closed with a 0.21% decline, trading at a daily volume of $210 million, a 50.01% drop from the previous day’s activity, ranking it 489th in market liquidity. The biopharma firm announced a high-profile partnership with tennis legend Monica Seles, who publicly disclosed her five-year battle with myasthenia gravis (MG), a chronic autoimmune condition. Seles will champion argenx’s “Go for Greater” initiative at the 2025 U.S. Open, aiming to amplify awareness of MG and connect patients with support networks. The collaboration aligns with argenx’s broader efforts to address neuromuscular diseases through patient advocacy and community engagement.

Seles, a nine-time Grand Slam champion, emphasized the emotional and physical toll of MG, sharing her journey to inspire others affected by the disease. “By sharing my story, I can empower patients to advocate for themselves and build a supportive community,” she stated. The partnership underscores argenx’s commitment to advancing patient-centric programs, including its Go for Greater platform, which provides resources and fosters connections among MG patients. The firm also highlighted its role as a premier global sponsor of the 2025 U.S. Open to further elevate the campaign’s reach.

The initiative targets a U.S. population of over 120,000 individuals living with MG, a condition marked by muscle weakness, fatigue, and vision impairment. Karen Massey, argenx’s COO, praised Seles’ advocacy, noting her efforts will amplify patient voices and drive meaningful conversations around MG. The partnership builds on argenx’s existing focus on autoimmune therapies, including its commercialized neonatal Fc receptor blocker, and reinforces its position in the immunology sector.

A backtest of the strategy involving the top 500 stocks by daily trading volume held for one day showed a total profit of $2,550 from 2022 to the present. However, the approach faced a maximum drawdown of -15.2% on October 27, 2022, highlighting the volatility inherent in volume-driven trading strategies. While profitable overall, the results indicate significant short-term risks.